VIRMA and intrahepatic cholangiocarcinoma: Crucially, the combination of ANLN and VIRMA or IGF2BP3 offers a greater predictive value compared than each marker alone, highlighting the enhanced accuracy of these genes as biomarkers in forecasting the prognosis of ICC patients.